Javascript must be enabled to continue!
Total Arch Replacement for Aortic Arch Aneurysm with Cold Agglutinin Disease after Rituximab and Plasmapheresis
View through CrossRef
Abstract
Background:
Cold agglutinin disease can lead to significant complications, specifically for patients undergoing arch repair requiring hypothermic circulatory arrest. Rituximab and plasmapheresis are treatments for cold agglutinin disease; therefore, we used them under consultation of hematologists before mild hypothermic aortic arch surgery maintaining the body temperature above thermal altitude.
Case presentation:
We describe an 86-year-old male with acute Type A aortic dissection who had been treated for rheumatoid arthritis and a 55-mm thoracic aortic aneurysm as an outpatient. The patient was scheduled to undergo urgent surgery for a Type A intramural hematoma and progressive aortic aneurysm; however, blood clotting was observed on a laboratory test and cold agglutinin was detected. Consequently, we rescheduled the urgent surgery. Under consultation of hematologists, rituximab was initiated 3 months before surgery, and plasmapheresis was performed 2 days before surgery for cold agglutinin disease. Then, total arch replacement under mild hypothermia with the frozen elephant trunk technique was performed by maintaining cerebral and lower body perfusion. The postoperative course was uneventful. On the 42nd postoperative day, the patient was discharged without any neurological deficits.
Conclusions:
We report a case of total arch replacement with mild hypothermia for aortic arch aneurysm with cold agglutinin disease after rituximab treatment and plasmapheresis.
Research Square Platform LLC
Title: Total Arch Replacement for Aortic Arch Aneurysm with Cold Agglutinin Disease after Rituximab and Plasmapheresis
Description:
Abstract
Background:
Cold agglutinin disease can lead to significant complications, specifically for patients undergoing arch repair requiring hypothermic circulatory arrest.
Rituximab and plasmapheresis are treatments for cold agglutinin disease; therefore, we used them under consultation of hematologists before mild hypothermic aortic arch surgery maintaining the body temperature above thermal altitude.
Case presentation:
We describe an 86-year-old male with acute Type A aortic dissection who had been treated for rheumatoid arthritis and a 55-mm thoracic aortic aneurysm as an outpatient.
The patient was scheduled to undergo urgent surgery for a Type A intramural hematoma and progressive aortic aneurysm; however, blood clotting was observed on a laboratory test and cold agglutinin was detected.
Consequently, we rescheduled the urgent surgery.
Under consultation of hematologists, rituximab was initiated 3 months before surgery, and plasmapheresis was performed 2 days before surgery for cold agglutinin disease.
Then, total arch replacement under mild hypothermia with the frozen elephant trunk technique was performed by maintaining cerebral and lower body perfusion.
The postoperative course was uneventful.
On the 42nd postoperative day, the patient was discharged without any neurological deficits.
Conclusions:
We report a case of total arch replacement with mild hypothermia for aortic arch aneurysm with cold agglutinin disease after rituximab treatment and plasmapheresis.
Related Results
Blood pressure, hypertension, and the risk of aortic aneurysm in the UK Biobank
Blood pressure, hypertension, and the risk of aortic aneurysm in the UK Biobank
Abstract
Background
Although an association between elevated blood pressure and risk of aortic aneurysm is established, f...
Mortality After Elective and Ruptured Abdominal Aortic Aneurysm Surgical Repair: 12-Year Single-Center Experience of Estonia
Mortality After Elective and Ruptured Abdominal Aortic Aneurysm Surgical Repair: 12-Year Single-Center Experience of Estonia
Background and Aims:
Abdominal aortic aneurysm is a degenerative vascular pathology with high mortality due to its rupture, which is why timely treatment is cru...
Could rituximab be a silver lining in refractory bone marrow fibrosis caused by lupus?
Could rituximab be a silver lining in refractory bone marrow fibrosis caused by lupus?
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that can present with a variety of clinical manifestations, ranging from mild skin involvement to multisystemic ...
AORTIC ROOT ANEURYSM OR ECTASIA TREATED WITH AORTIC ROOT WRAPPED PROCEDURE
AORTIC ROOT ANEURYSM OR ECTASIA TREATED WITH AORTIC ROOT WRAPPED PROCEDURE
Objectives
To develop a relatively simple and effective and less risk operation, aortic root wrapped procedure, to treat with aortic root aneurysm or ectasia.
...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Aortic root wrapped procedure
Aortic root wrapped procedure
Objective
To develop a relatively simple and effective and less risk operation, aortic root wrapped procedure, to treat with aortic root aneurysm or ectasia.
...
Investigation on “Cold” or Auto-Hemoagglutination
Investigation on “Cold” or Auto-Hemoagglutination
Summary and Conclusions
“Cold” or auto-agglutination was observed in the blood of a patient suffering from syphilitic liver cirrhosis with ascites and aortic regurgi...
Rituximab Induces Long Lasting Clinical and Serological Remission in Refractory Antiphospholipid Syndrome (APS) and Related Disorders.
Rituximab Induces Long Lasting Clinical and Serological Remission in Refractory Antiphospholipid Syndrome (APS) and Related Disorders.
Abstract
INTRODUCTION. Rituximab, a chimeric monoclonal antibody against CD20 expressed on B cells, has been approved for the treatment of B cell neoplasms. Recently...

